The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,556.00
Bid: 12,588.00
Ask: 12,590.00
Change: -34.00 (-0.27%)
Spread: 2.00 (0.016%)
Open: 12,626.00
High: 12,646.00
Low: 12,474.00
Prev. Close: 12,590.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Work-from-home guidance and face masks can be back in winter in UK

Mon, 13th Sep 2021 11:19

(Alliance News) - Guidance to work from home and the mandatory use of face masks are likely to be retained as options in the Covid winter plan due to be set out by UK Prime Minister Boris Johnson.

The prime minister will tell the nation on Tuesday how the country can learn to live with the virus, underlining how vaccinations will be a central part of the response to coronavirus in the coming months.

Covid laws that are no longer required will be ditched and plans for vaccine passports for nightclubs and other large crowd venues have been shelved.

The travel traffic lights system is also expected to be scrapped and PCR tests will no longer be required for fully vaccinated travellers.

Speaking on Monday, Work & Pensions Secretary Therese Coffey said some regulations may still be needed as the NHS prepares to battle both Covid and seasonal flu in the winter months.

Asked about maintaining the work-from-home advice, she told BBC Breakfast of the need to keep some rules on the table, adding: "Whether that's with what you just mentioned or making sure statutory sick pay can be paid from day one rather than day four, as tends to happen in more regular times.

"These are the sensible measures I think that we're going to keep."

On the issue of masks, she added: "The prime minister will be setting out the Covid winter plan tomorrow. I think my approach, and I see that with a lot of employers' organisations, is about having a situation-specific approach."

It comes after Health Secretary Sajid Javid said on Sunday that vaccine passports were a "huge intrusion into people's lives" and there were no current plans to go ahead with them.

He said: "You have got to be really, really certain that's what you want to do. We have looked at it and whilst we will keep it in reserve I am pleased to say that we will not be going ahead."

However, Coffey said the introduction of vaccine passports had not been "ruled out forever".

She said: "As Sajid Javid set out yesterday, although the formal decision is still to be made, but having reflected and looked at the details of the proposal that it's not deemed necessary at this moment in time.

"But they haven't been ruled out forever. It's reflecting the fact that a lot of young people have come forward and got their vaccinations over the summer."

The government has yet to set out the plans for booster vaccinations, which are expected to be given to the most vulnerable people first.

A decision has also not yet been made by the UK's chief medical officers on extending the Covid vaccination programme to healthy 12 to 15-year-olds.

The Joint Committee on Vaccination & Immunisation has already said the margin of benefit is considered too small to support universal vaccination of healthy youngsters at this time.

Elsewhere, Neil Ferguson, whose modelling was instrumental to the UK going into lockdown in March 2020, has said he is in favour of a booster programme.

The scientist, from Imperial College London, and a member of the Scientific Advisory Group for Emergencies, told BBC Radio 4's Today programme on Monday that in the absence of social distancing measures, which he did agree with, "we are reliant on immunity building up in the population".

He added: "That happens two ways – one through vaccination, and one through people getting infected and so the faster we can roll our additional vaccination, the better in terms of stopping people getting severely ill but also in reducing transmission."

He said the UK had been leading in Europe on vaccination until recently but other countries such as Spain, Portugal, France, Italy and Ireland "have got higher vaccination levels than us and that's largely because they have rolled out vaccination of 12 to 15-year-olds faster than us.

"They also vaccinated more recently, and we know now that vaccine effectiveness decays over time, we always expected that, and so they have more immunity in the population.

"They also principally used the Pfizer vaccine which against Delta is somewhat more effective than the AstraZeneca vaccine, so there are a set of countries in Europe with considerably more population immunity than us and I think if we want to stop the risk of the large autumn and winter wave we need to boost immunity in the population."

Ferguson said vaccinating teenagers with a first shot was the priority as the UK looks at dealing with any autumn and winter surges in Covid. But he said evidence from Israel suggested booster shots for a wider population were "very effective at further driving down transmission and infection".

Asked whether a further lockdown could be ruled out, he said "I hope so" but added that "you can't rule out anything completely".

The issue of vaccine passports has caused growing disquiet among Tory ranks, as well as facing opposition from opposition parties and industry figures.

The decision not to implement them means measures in England deviate from those in Scotland, where a motion on their introduction was passed in the Scottish Parliament on Thursday, while a decision is expected in Wales next week.

Stormont ministers have yet to reach an official position on using vaccine access passports within Northern Ireland.

By Jane Kirby and Sam Blewett

source: PA

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
1 Dec 2023 08:52

LONDON MARKET OPEN: Miners give FTSE 100 boost thanks to China PMI

(Alliance News) - Stock prices in London opened higher on Friday, with the FTSE 100 boosted by mining stocks.

Read more
1 Dec 2023 08:33

AstraZeneca discontinues two phase III evidence trials for Lokelma

(Alliance News) - AstraZeneca on Friday said it has decided to discontinue the Stabilize-CKD and Dialize-outcomes phase III trials for Lokelma, citing increased enrolment timelines.

Read more
1 Dec 2023 08:01

AstraZeneca calls off two phase III trials into hyperkalaemia treatment

(Sharecast News) - Drugmaker AstraZeneca has called off two phase III trials on its hyperkalaemia treatment after a series of logistical challenges.

Read more
1 Dec 2023 07:41

LONDON BRIEFING: Stocks called higher; UK house prices fall annually

(Alliance News) - Stocks in London are called to open higher on Friday, following data from Nationwide showing that the annual pace of UK house price decline slowed in November.

Read more
27 Nov 2023 16:12

London close: Stocks start week in subdued state

(Sharecast News) - London's financial markets saw a somewhat subdued performance on Monday, as concerns regarding the Chinese economy cast a shadow over investor sentiment.

Read more
27 Nov 2023 09:20

LONDON BROKER RATINGS: Peel, Numis up Rightmove; Goldman cuts Entain

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
23 Nov 2023 18:41

IN BRIEF: AstraZeneca Chair Demare buys shares for over GBP200,000

AstraZeneca PLC - Cambridge-based pharmaceutical company - Chair Michel Demare buys 2,000 shares in total on Wednesday and Tuesday. Buys 1,000 shares for GBP101.05 each on Tuesday and 1,000 shares for GBP101.70 each on Thursday, for a total of GBP202,752.

Read more
20 Nov 2023 10:49

AstraZeneca launches new life sciences tech innovation firm Evinova

(Alliance News) - AstraZeneca PLC on Monday launched Evinova, a new health technology business focused on accelerating innovation across the life sciences sector, delivery of clinical trials and better health outcomes.

Read more
17 Nov 2023 15:20

London close: Stocks higher despite weaker retail sales data

(Sharecast News) - London's stock markets finished in a positive state on Friday despite weaker-than-expected UK retail sales figures.

Read more
17 Nov 2023 12:00

LONDON MARKET MIDDAY: Stocks shrug off downbeat UK retail sales

(Alliance News) - Stock prices in London were up at midday on Friday, as a week of favourable data as far as inflation goes gave investors a reason to overlook disappointing UK retail sales figures.

Read more
17 Nov 2023 09:03

LONDON MARKET OPEN: Stocks up despite UK retail sales growth miss

(Alliance News) - Stock prices in London opened higher on Friday, despite weaker-than-expected October retail sales figures for the UK.

Read more
17 Nov 2023 08:31

TOP NEWS: US approves AstraZeneca's Truqap for form of breast cancer

(Alliance News) - AstraZeneca PLC on Friday said that the US Food & Drug Administration approved its drug Truqap in combination with Faslodex to treat patients with an advanced form of breast cancer.

Read more
17 Nov 2023 07:58

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.

Read more
17 Nov 2023 07:16

AstraZeneca gets US approval for breast cancer treatment

(Sharecast News) - AstraZeneca's 'Truqap', or capivasertib, in combination with 'Faslodex', or fulvestrant, has secured approval from the US Food and Drug Administration (FDA) for specific breast cancer treatments, the company announced on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.